Blueprint Medicines Corp
Blueprint Medicines Corp logo
BPMC

Blueprint Medicines Corp (BPMC)

$47.490.63%

Market is closed
– opens on 8 PM, 02 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$47.3
Day's Range
$48.41
$40.78
52-Week Range
$111.78
1 month return3.02%
3 month return34.87%
1 year return51.79%
5 year return31.87%

Company Information

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.
OrganizationBlueprint Medicines Corp
Employees602
CEOMr. Jeffrey W. Albers J.D., M.B.A., MBA
IndustryHealth Technology

Analyst Recommendation

based on 14 analysts ratings

Buy
64%
Buy
35%
Hold
0%
Sell

Based on 14 Wall street analysts offering stock ratings for Blueprint Medicines Corp(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 65.82%

Current

$47.49

Target

$78.75

Recommendation Trend

Based on 14 analyst

Current1M Ago3M Ago
Buy
9
17
16
Hold
5
5
5
Sell
0
2
2
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
2.9B
Book Value
$10.71
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-11.06
PEG Ratio
0.0
Wall Street Target Price
78.75

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
4.23
Enterprise Value
1.8B
Enterprise Value/Revenue
6.66
Enterprise Value/Ebitda
-2.6

Technicals

Beta
0.66
50 Day MA
51.9
200 Day MA
59.13

Institutional Holdings

FMR Inc

14.33%

Vanguard Group Inc

9.46%

T. Rowe Price Associates, Inc.

9.41%

Wellington Management Company LLP

6.39%

State Street Corporation

3.71%

JPMorgan Chase & Co

2.88%

Discover more

Frequently Asked Questions

What is Blueprint Medicines Corp share price today?

Can Indians buy Blueprint Medicines Corp shares?

How can I buy Blueprint Medicines Corp shares from India?

Can Fractional shares of Blueprint Medicines Corp be purchased?

What are the documents required to start investing in Blueprint Medicines Corp stocks?

What are today’s High and Low prices of Blueprint Medicines Corp?

What are today’s traded volumes of Blueprint Medicines Corp?

What is today’s market capitalisation of Blueprint Medicines Corp?

What is the 52 Week High and Low Range of Blueprint Medicines Corp?

How much percentage Blueprint Medicines Corp is down from its 52 Week High?

How much percentage Blueprint Medicines Corp is up from its 52 Week low?

What are the historical returns of Blueprint Medicines Corp?

Who is the Chief Executive Officer (CEO) of Blueprint Medicines Corp?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*